ASMBAssembly Biosciences, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $25.48 · now $25.48 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ASMB has typically landed between $19.65 and $33.87 — a range of −22.9% to +32.9% from the issuance price $25.48.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,935 overlapping 1 month windows · 2010-12-172026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($25.48) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ASMB has typically landed a month from the 2026-09-16 close of $25.48 — the range is history, not a prediction.

$19.65worst · -22.9%$33.87best · +32.9%
  • now $25.48 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $25.21 (-1.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $22.3$28.13
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $19.65$33.87
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,935 windows spanning 2010-12-17 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2012-06-22−69.3%−71.0%+0.0%
2014-02-10−68.8%−69.5%+0.0%
2012-06-20−68.6%−70.1%+3.1%
3 best
2019-10-10+101.7%+0.0%+101.7%
2016-09-30+95.8%+0.0%+95.8%
2019-10-09+94.0%+0.0%+103.5%

3,935 overlapping windows · 2010-12-172026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~16 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
56%
+2.3%
n=16
Feb
56%
+3.3%
n=16
Mar
31%
−1.1%
n=16
Apr
38%
+1.4%
n=16
May
56%
+5.7%
n=16
Jun
38%
−1.6%
n=16
Jul
25%
−4.2%
n=16
Aug
56%
+4.9%
n=16
Sep
31%
−4.6%
n=16
Oct
33%
+6.4%
n=15
Nov
47%
−3.3%
n=15
Dec
40%
−0.5%
n=15

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$39$212026-06-17: 1 insider sale, $674 — Bjorkquist Jeanette M2026-03-30: 4 insider sales, $14K — Bjorkquist Jeanette M, White Nicole S …2026-03: 4 open-market sales, $14K2026-06: 1 open-market sale, $674↑ buys↓ salesofficer Bjorkquist Jeanette M — Sale on 2026-06-17, filed 1 day after the tradeofficer Bjorkquist Jeanette M — Sale on 2026-03-30, filed 1 day after the tradeofficer White Nicole S — Sale on 2026-03-30, filed 1 day after the tradeofficer Bjorkquist Jeanette M — Sale on 2026-03-30, filed 1 day after the tradeofficer White Nicole S — Sale on 2026-03-30, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-06-17Bjorkquist Jeanette MofficerSale29 @ $23.25$674−0.2% of holding+3.4%not yet — horizon still open14,560Form 4 · filed 1 day after the trade
2026-03-30Bjorkquist Jeanette MofficerSale312 @ $26.65$8K−2.7% of holding−13.8%not yet — horizon still open11,105Form 4 · filed 1 day after the trade
2026-03-30White Nicole SofficerSale188 @ $26.65$5K−0.5% of holding−13.8%not yet — horizon still open37,486Form 4 · filed 1 day after the trade
2026-03-30Bjorkquist Jeanette MofficerSale16 @ $27.49$440−0.1% of holding−13.8%not yet — horizon still open11,089Form 4 · filed 1 day after the trade
2026-03-30White Nicole SofficerSale9 @ $27.49$247−0.0% of holding−13.8%not yet — horizon still open37,477Form 4 · filed 1 day after the trade
2025-08-08GILEAD SCIENCES, INC.tenPercentOwnerPurchase1,147,960ownership Δ n/a−5.5%+2.7%1,147,960Form 4 · filed 56 days after the trade
2025-08-08GILEAD SCIENCES, INC.tenPercentOwnerPurchase2,295,920+103.9% of holding−5.5%+2.7%4,505,391Form 4 · filed 56 days after the trade
2025-08-08GILEAD SCIENCES, INC.tenPercentOwnerPurchase1,147,960ownership Δ n/a−5.5%+2.7%1,147,960Form 4 · filed 56 days after the trade
2025-08-08GILEAD SCIENCES, INC.tenPercentOwnerPurchase2,295,920+103.9% of holding−5.5%+2.7%4,505,391Form 4 · filed 56 days after the trade
2025-08-08GILEAD SCIENCES, INC.tenPercentOwnerPurchase1,147,960ownership Δ n/a−5.5%+2.7%1,147,960Form 4 · filed 56 days after the trade
2025-08-08GILEAD SCIENCES, INC.tenPercentOwnerPurchase1,147,960ownership Δ n/a−5.5%+2.7%1,147,960Form 4 · filed 56 days after the trade
2025-03-31McHutchison John GdirectorSale757 @ $9.85$7K−4.0% of holding+20.0%+148.0%18,347Form 4 · filed 15 days after the trade
2025-03-31Okazaki Jason AdirectorSale355 @ $9.85$3K−2.3% of holding+20.0%+148.0%14,757Form 4 · filed 1 day after the trade
2025-03-31White Nicole SofficerSale197 @ $9.85$2K−1.7% of holding+20.0%+148.0%11,674Form 4 · filed 1 day after the trade
2025-03-31Bjorkquist Jeanette MofficerSale180 @ $9.85$2K−3.8% of holding+20.0%+148.0%4,617Form 4 · filed 1 day after the trade
2024-12-30Houghton MichaeldirectorPurchase3,202 @ $15.61$50Kownership Δ n/a−14.9%+6.2%3,202Form 4 · filed 1 day after the trade
2024-12-19GILEAD SCIENCES, INC.tenPercentOwnerPurchase940,499 @ $21.37$20.1M+74.1% of holding−10.3%+4.9%2,209,471Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

32 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-04ALTIG ANTHONY EdirectorAward / grant8,0008,000Form 4
2026-06-04McHutchison John GdirectorAward / grant8,0008,000Form 4
2026-06-04Houghton MichaeldirectorAward / grant8,0008,000Form 4
2026-06-04Johnson-Pratt LisadirectorAward / grant8,0008,000Form 4
2026-06-04Mahony SusandirectorAward / grant8,0008,000Form 4
2026-06-04Consylman GinadirectorAward / grant8,0008,000Form 4
2026-05-26GILEAD SCIENCES, INC.tenPercentOwnerAward / grant471,6984,977,089Form 4
2026-03-29White Nicole SofficerAward / grant14,00048,145Form 4
2026-03-29Delaney William E IVofficerAward / grant26,00045,642Form 4
2026-03-29Okazaki Jason AdirectorAward / grant94,250111,916Form 4
2026-03-29Gaggar AnujofficerAward / grant26,00028,000Form 4
2026-03-29White Nicole SofficerAward / grant26,00037,674Form 4
2026-03-29Bjorkquist Jeanette MofficerAward / grant3,50014,589Form 4
2026-03-29Bjorkquist Jeanette MofficerAward / grant6,50011,417Form 4
2026-03-29Delaney William E IVofficerAward / grant14,00060,330Form 4
2026-03-29Gaggar AnujofficerAward / grant14,00042,688Form 4
2026-03-29Okazaki Jason AdirectorAward / grant50,750163,354Form 4
2025-06-16Bjorkquist Jeanette MofficerAward / grant600600Form 4
2025-06-16Bjorkquist Jeanette MofficerAward / grant3005,097Form 4
2025-06-05McHutchison John GdirectorAward / grant3,5003,500Form 4
2025-06-05Johnson-Pratt LisadirectorAward / grant3,5003,500Form 4
2025-06-05Mahony SusandirectorAward / grant3,5003,500Form 4
2025-06-05Houghton MichaeldirectorAward / grant3,5003,500Form 4
2025-06-05ALTIG ANTHONY EdirectorAward / grant3,5003,500Form 4
2025-06-05RINGO WILLIAM RdirectorAward / grant3,5003,500Form 4
2025-06-05Consylman GinadirectorAward / grant3,5003,500Form 4
2025-03-29Bjorkquist Jeanette MofficerAward / grant1,6554,797Form 4
2025-03-29Delaney William E IVofficerAward / grant25,50025,500Form 4
2025-03-29Bjorkquist Jeanette MofficerAward / grant1,9001,900Form 4
2025-03-29Gaggar AnujofficerAward / grant24,20024,200Form 4
2025-03-29White Nicole SofficerAward / grant20,40020,400Form 4
2025-03-29Okazaki Jason AdirectorAward / grant71,10071,100Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.